Tags

Type your tag names separated by a space and hit enter

Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study.
Ren Fail. 2007; 29(3):271-7.RF

Abstract

PURPOSE

The aim of this pilot study was to compare the effect of heparin anticoagulation with and without iloprost administration during continuous renal replacement therapy (CRRT) in critically ill patients.

MATERIAL AND METHODS

In a prospective, randomized, controlled pilot study at an intensive care unit at a university hospital, 20 patients requiring CRRT were investigated. Patients were allocated into two groups: group 1, the heparin group; and group 2, the heparin plus 1 ng/kg/min iloprost. In both groups, activated partial thromboplastin time (aPTT) was adjusted to 40-50 sec. Observation time was a maximum of 7 days.

RESULTS

Median filter run time was significantly prolonged by iloprost administration to a median of 14 h (13-26 h) compared to 10 h (4-12 h) in the heparin group (p = 0.004). A decrease in platelet count was attenuated by iloprost administration (p = 0.012). There were no bleeding complications in either group. Hemofiltration efficiency did not differ significantly between the groups.

CONCLUSION

Additional administration of iloprost prolonged the filter run time of continuous veno-venous hemofiltration (CVVH) in this setting and attenuated the fall in platelet count during CRRT.

Links

Publisher Full Text

Authors+Show Affiliations

Birnbaum J
Department of Anesthesiology and Intensive Care Medicine, Campus Charité Mitte and Campus Charité Virchow-Klinikum, Charité-University Medicine, Berlin, Germany. juergen.birnbaum@charite.de
Spies CD
No affiliation info available
Klotz E
No affiliation info available
Hein OV
No affiliation info available
Morgera S
No affiliation info available
Schink T
No affiliation info available
Ziemer S
No affiliation info available
Grund MS
No affiliation info available
Saalmann R
No affiliation info available
Kox WJ
No affiliation info available
Lehmann C
No affiliation info available

MeSH

Acute Kidney InjuryAgedAged, 80 and overAnalysis of VarianceAnticoagulantsBiomarkersBlood CoagulationDrug Therapy, CombinationFemaleHemofiltrationHeparinHumansIloprostInfusions, IntravenousMaleMiddle AgedPartial Thromboplastin TimePilot ProjectsPlatelet ActivationPlatelet Aggregation InhibitorsPlatelet CountProspective StudiesTreatment Outcome

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

17497439

Citation

Birnbaum, Jürgen, et al. "Iloprost for Additional Anticoagulation in Continuous Renal Replacement Therapy--a Pilot Study." Renal Failure, vol. 29, no. 3, 2007, pp. 271-7.
Birnbaum J, Spies CD, Klotz E, et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Ren Fail. 2007;29(3):271-7.
Birnbaum, J., Spies, C. D., Klotz, E., Hein, O. V., Morgera, S., Schink, T., Ziemer, S., Grund, M. S., Saalmann, R., Kox, W. J., & Lehmann, C. (2007). Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure, 29(3), 271-7.
Birnbaum J, et al. Iloprost for Additional Anticoagulation in Continuous Renal Replacement Therapy--a Pilot Study. Ren Fail. 2007;29(3):271-7. PubMed PMID: 17497439.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. AU - Birnbaum,Jürgen, AU - Spies,Claudia D, AU - Klotz,Edda, AU - Hein,Ortrud Vargas, AU - Morgera,Stanislao, AU - Schink,Tania, AU - Ziemer,Sabine, AU - Grund,Mona S, AU - Saalmann,René, AU - Kox,Wolfgang J, AU - Lehmann,Christian, PY - 2007/5/15/pubmed PY - 2008/4/5/medline PY - 2007/5/15/entrez SP - 271 EP - 7 JF - Renal failure JO - Ren Fail VL - 29 IS - 3 N2 - PURPOSE: The aim of this pilot study was to compare the effect of heparin anticoagulation with and without iloprost administration during continuous renal replacement therapy (CRRT) in critically ill patients. MATERIAL AND METHODS: In a prospective, randomized, controlled pilot study at an intensive care unit at a university hospital, 20 patients requiring CRRT were investigated. Patients were allocated into two groups: group 1, the heparin group; and group 2, the heparin plus 1 ng/kg/min iloprost. In both groups, activated partial thromboplastin time (aPTT) was adjusted to 40-50 sec. Observation time was a maximum of 7 days. RESULTS: Median filter run time was significantly prolonged by iloprost administration to a median of 14 h (13-26 h) compared to 10 h (4-12 h) in the heparin group (p = 0.004). A decrease in platelet count was attenuated by iloprost administration (p = 0.012). There were no bleeding complications in either group. Hemofiltration efficiency did not differ significantly between the groups. CONCLUSION: Additional administration of iloprost prolonged the filter run time of continuous veno-venous hemofiltration (CVVH) in this setting and attenuated the fall in platelet count during CRRT. SN - 0886-022X UR - https://www.unboundmedicine.com/medline/citation/17497439/Iloprost_for_additional_anticoagulation_in_continuous_renal_replacement_therapy__a_pilot_study_ L2 - https://www.tandfonline.com/doi/full/10.1080/08860220601166222 DB - PRIME DP - Unbound Medicine ER -